Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PARKINSON DISEASE

Digital assessment at home — mPower against Parkinson disease

Results of a new study have shown the enormous potential of smartphone-collected, real-world data for the differentiation of patients with Parkinson disease from controls. This study spearheads a new phase for the evaluation of symptoms associated with Parkinson disease that is patient-centred, digital, objective, continuous and relevant to everyday life.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    van den Heuvel, L. et al. Quadruple decision making for Parkinson’s disease patients: combining expert opinion, patient preferences, scientific evidence, and big data approaches to reach precision medicine. J. Parkinsons Dis. 10, 223–231 (2020).

    Article  Google Scholar 

  2. 2.

    Dorsey, E. R., Glidden, A. M., Holloway, M. R., Birbeck, G. L. & Schwamm, L. H. Teleneurology and mobile technologies: the future of neurological care. Nat. Rev. Neurol. 14, 285–297 (2018).

    Article  Google Scholar 

  3. 3.

    Omberg, L. et al. Remote smartphone monitoring of Parkinson’s disease and individual response to therapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-021-00974-9 (2021).

    Article  PubMed  Google Scholar 

  4. 4.

    US Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices (2017).

  5. 5.

    Husain, M. Time for N-of-1 trials in clinical decision-making. Brain 144, 1031–1032 (2021).

    Article  Google Scholar 

  6. 6.

    Manta, C., Patrick-Lake, B. & Goldsack, J. C. Digital measures that matter to patients: a framework to guide the selection and development of digital measures of health. Digit. Biomark. 4, 69–77 (2020).

    Article  Google Scholar 

  7. 7.

    Coran, P. et al. Advancing the use of mobile technologies in clinical trials: recommendations from the clinical trials transformation initiative. Digit. Biomark. 3, 145–154 (2019).

    Article  Google Scholar 

  8. 8.

    US Food and Drug Administration. Drug development tool. Letter of intent determination. DDT COA #000142. FDA https://www.fda.gov/media/149517/download (2021).

  9. 9.

    Morgan, C. et al. Systematic Review looking at the use of technology to measure free-living symptom and activity outcomes in Parkinson’s disease in the home or a home-like environment. J. Parkinsons Dis. 10, 429–454 (2020).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Walter Maetzler.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

IDEA-FAST: https://idea-fast.eu/

Mobilise-D: https://www.mobilise-d.eu/

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Maetzler, W., Pilotto, A. Digital assessment at home — mPower against Parkinson disease. Nat Rev Neurol 17, 661–662 (2021). https://doi.org/10.1038/s41582-021-00567-9

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing